amelimumab (SY101) / Tasly - LARVOL DELTA

SY101. Automated Anesthesia Delivery, the US Experience (non-CME) (ASA 2024) - "DESCRIPTION Join three leading anesthesiologists as they present real-world outcomes of automated inhalational anesthesia delivery using End-tidal Control, demonstrating how it impacts patient care, drives efficiency, and reduces anesthetic agent usage. GE Healthcare, Corporate Supporter"

Anesthesia

SY101. Checkpoints on Anti-Osteoporosis Medications: Clinical and Biological Considerations (ENDO 2023) - "DESCRIPTION The rationale for and approach to drug holidays in the setting of bisphosphonate therapy may not translate well to other anti-osteoporosis medications, as simple discontinuation of some such drugs may worsen fracture risk. Therefore, appropriate sequences and suitable timing for stopping anti-osteoporosis medication are of greatest interest to both doctors and patients."

Clinical • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

A phase Ia dose-escalation trial of Ametumumab (a fully human monoclonal antibody against epidermal growth factor receptor) in patients with advanced solid malignancies. (PubMed, Ther Adv Med Oncol) - "The Ametumumab was well tolerated and safe in patients with advanced solid malignancies, exhibiting minimal immunogenicity, a long half-life, high levels of drug exposure in the blood, and preliminary effectiveness. The trial was registered with CTR20170343 on 10 April 2017, The China Center for Drug Evaluation."

Journal • Metastases • P1 data • Oncology • Pain • Renal Disease • Solid Tumor • EGFR

A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer (clinicaltrials.gov) - P2b | N=84 | Not yet recruiting | Sponsor: Shanghai Celfuture Biotech Co., Ltd.

Combination therapy • Metastases • New P2b trial • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • KRAS • NRAS • RAS